

## **D-RIBOSE SUPPLEMENTATION IMPROVES PEAK EXERCISE CAPACITY AND VENTILATORY EFFICIENCY IN HEART FAILURE PATIENTS**

Orly Carter, Dean MacCarter, Steve Mannebach, Joseph Biskupiak, Greg Stoddard, Edward M. Gilbert, Mark A. Munger, Departments of Internal Medicine and Pharmacotherapy, University of Utah, Salt Lake City, UT

**Background:** Many clinicians and scientists concur that the failing heart is energy starved. D-Ribose (dR), a naturally occurring monosaccharide, has been shown to increase myocardial high-energy phosphate stores and improve post-ischemic myocardial function in humans. This study was designed to determine whether dR could improve maximal exercise capacity and ventilatory efficiency, a powerful independent predictor of heart failure (HF) survival, in subjects with NYHA II-III HF.

**Methods:** Fourteen subjects with HF of ischemic etiology (LVEF: 32.4±8.1) completed a single-center study, using a randomized, double-blind, placebo-controlled (PL), cross-over design. Each subject underwent maximal cycle ergometry with gas exchange monitoring, quality of life (QOL, DASI questionnaire), and BNP levels at baseline and the end of each 8-week cross-over phase with a 2-week washout phase. Ventilatory efficiency was assessed using the linear VE to VCO<sub>2</sub> slope. dR or PL was administered on a 5 gram TID schedule in addition to standard systolic HF drug regimens.

**Results:** dR significantly maintained VO<sub>2</sub>max vs. PL, while improving the VE/VCO<sub>2</sub> relationship, up to the respiratory compensation point (RCP), and the RCP. (Table 1) There was no significant difference in QOL scores or BNP levels.

**Conclusions:** dR maintains maximal exercise capacity while improving ventilation efficiency, a strong predictor of HF survival, in NYHA II-III HF. dR may offer adjunctive, metabolic therapy for HF.

	<b>VO<sub>2</sub>max (%change) [mean±SD]</b>	<b>VE/VCO<sub>2</sub>@AT (%change) [mean±SD]</b>	<b>RCP (%change) [mean±SD]</b>
<b>D-Ribose</b>	-1.4±8.5 (p=0.02 vs. PL)	4.9±-6.4 (p=0.08 vs. PL)	5.8±9.8 (p=0.03 vs. PL)
<b>Placebo</b>	-7.8±7.3	-6.9±9.1	-1.4±8.5

Abstract Presentation at:  
**American College of Cardiology  
Annual Scientific Session 2005**  
Orlando, FL  
March 6-9, 2005